Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
